0000950170-24-011253.txt : 20240205 0000950170-24-011253.hdr.sgml : 20240205 20240205162135 ACCESSION NUMBER: 0000950170-24-011253 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240201 FILED AS OF DATE: 20240205 DATE AS OF CHANGE: 20240205 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Weber Barbara CENTRAL INDEX KEY: 0001800670 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39485 FILM NUMBER: 24596004 MAIL ADDRESS: STREET 1: C/O REVOLUTION MEDICINES, INC. STREET 2: 700 SAGINAW DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Tango Therapeutics, Inc. CENTRAL INDEX KEY: 0001819133 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 201 BROOKLINE AVENUE STREET 2: SUITE 901 CITY: BOSTON STATE: MA ZIP: 02215 BUSINESS PHONE: (857) 320-4900 MAIL ADDRESS: STREET 1: 201 BROOKLINE AVENUE STREET 2: SUITE 901 CITY: BOSTON STATE: MA ZIP: 02215 FORMER COMPANY: FORMER CONFORMED NAME: BCTG Acquisition Corp. DATE OF NAME CHANGE: 20200723 4 1 ownership.xml 4 X0508 4 2024-02-01 0001819133 Tango Therapeutics, Inc. TNGX 0001800670 Weber Barbara C/O TANGO THERAPEUTICS, INC., 201 BROOKLINE AVE., SUITE 901 BOSTON MA 02215 true true false false Chief Executive Officer false Common Stock 2024-02-01 4 A false 87168 0.00 A 87168 D Stock Option (Right to Buy) 12.28 2024-02-01 4 A false 523012 0.00 A 2034-02-01 Common Stock 523012 523012 D These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest over a three year period at a rate of 1/3 on February 3, 2025, 1/3 on February 2, 2026 and 1/3 on February 1, 2027, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. This option shall vest and become exercisable over a four-year period, at a rate of 25% on January 1, 2025, with the remaining option shares vesting in 36 equal monthly installments thereafter. /s/ Douglas Barry, attorney-in-fact 2024-02-05